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How Does IL-17 Mediate Antifungal Immunity?
The IL-17 cytokine family has emerged as a central component
of the host immune system since its discovery two decades ago. IL-
17A and IL-17F, the two signature cytokines collectively referred
to as IL-17 in the following, have attracted much attention owing
to their pathological potential and their ability to promote
autoimmune diseases such as psoriasis and rheumatoid arthritis.
It has become clear however that IL-17 also plays a key role in
host protection from infection with extracellular bacteria and
fungi. IL-17A and IL-17F homo- and heterodimers bind to a
heterodimeric complex composed of IL-17RA and RC receptor
subunits and trigger a signaling cascade that results in the
activation of NF-kB and MAPK [1]. This results in the production
of antimicrobial compounds and inflammatory mediators includ-
ing G-CSF and CXC chemokines, which are believed to be the
primary basis for recruitment and activation of neutrophils [1].
Recently, inborn errors in components of the IL-17 pathway have
been associated with an increased susceptibility to fungal
infections, first and foremost chronic mucocutaneous candidiasis
(CMC). These include defects in the genes encoding IL-17F or IL-
17RA [2]. Genome-wide association studies with patients suffering
from CMC have identified additional polymorphisms that cause
defects in the IL-17 response [2], clearly indicating that the IL-17
pathway plays a non-redundant role in antifungal immunity. This
notion is supported by studies using animal models: mice deficient
in IL-17 signaling or unable to mount robust IL-17 production are
strongly impaired to control skin and mucosal infections with
Candida albicans [3,4]. In mice, IL-17 has also been shown to
protect from other fungal infections including those caused by
Pneumocystis carinii [5], Histoplasmacapsulatum [6], and Aspergillus
fumingatus [7]. In line with its protective role at mucocutaneous
surfaces, IL-17 acts mainly on epithelial cells of the skin and
mucosal tissues. The cellular source of IL-17 however varies and
depends on the inflammatory context and the site of infection.
Which Cellular Sources Provide IL-17 during
Fungal Infection?
CD4+ T cells are widely accepted as the major producers of IL-
17 in response to fungal infection [8]. The differentiation of naı¨ve
T cells into Th17 effector cells is instructed by IL-6, which induces
the essential transcriptional regulator RORct, whereas IL-1b and
IL-23 are involved in the maintenance of Th17 cells [8]. The
cytokines necessary for Th17 differentiation are delivered mainly
by antigen presenting cells, which recognize conserved fungal
molecular patterns through C-type lectin receptors and Toll like
receptors [8]. Differentiation of T cells into Th17 effector cells
however is slow and takes up to a week. In contrast, the IL-17-
dependent antifungal response is initiated within hours of initial
pathogen encounter and the requirement for IL-17 to restrict
fungal replication and dissemination manifests long before the
Th17 developmental program is initiated, as studies in mouse
models demonstrated [3,4,9,10]. These findings clearly indicate
the involvement of other cellular sources for IL-17. Subsets of cd T
cells and NKT cells as well as the more recently identified innate
lymphoid cells (ILCs) act as important effectors of innate immunity
providing IL-17 in response to specific stimuli [11]. As their name
implies, ILCs are of lymphoid origin, but in contrast to
lymphocytes they do not express RAG-dependent rearranged
antigen-specific receptors [12]. Divided into three groups, ILCs
mirror conventional T cell subsets based on their expression of
specific transcription factors (Tbet, GATA3, RORct) along with
their ability to produce Th1, Th2, or Th17-associated cytokines
[12]. IL-17 and IL-22 producing ILCs were termed ILC3 [12].
Similar to pathogenic Th17 cells, IL-17-secreting ILC3s have been
implicated in the induction of colitis in mice and humans [13,14].
In addition, ILC3s contribute to tissue repair and homeostasis
[15]. Most importantly and in line with the host-protective
function of IL-17 in the context of fungal infection, ILC3s have
recently been implicated in the acute response to C. albicans [9].
Depletion of ILC3s renders mice highly susceptible to oropharyn-
geal candidiasis as does a deficiency in the IL-17 pathway [9]. In
contrast, the lack of IL-22, another central ILC3 cytokine, only
leads to a mild impairment in protection from oropharyngeal and
cutaneous candidiasis [6,7]. While ILC3s constitute a major source
of IL-17 at mucosal surfaces, cd T cells appear to be more
important in the skin: they secrete high amounts of IL-17 during
cutaneous candidiasis [16], albeit their contribution to protection
from skin infection has not yet been formally proven. Finally, it
remains to be demonstrated whether IL-17-dependent innate
immunity to fungal pathogens other than C. albicans also involves
cd T cells and ILC3s.
How Is IL-17 Production by ILCs Regulated?
In contrast to their adaptive counterparts that undergo a
complicated developmental program to differentiate into T helper
cell subsets upon immune activation, the functional commitment
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of innate IL-17 secreting cells is appointed during development.
They constitutively express the lineage-specific transcription factor
RORct as well as receptors that allow them to promptly respond
to cytokine stimulation induced upon microbial encounter. IL-23
and/or IL-1b, which are also involved in Th17 differentiation, act
as key factors in the induction of innate IL-17 [11]. However, the
relative role of each of these two cytokines appears to be context
dependent. While innate IL-17 induction can occur independently
of IL-23 in some cases [17], ILC3-derived IL-17 in the oral
mucosa is strictly dependent on IL-23 and not affected by IL-1
receptor deficiency [9]. In the gut mucosa, IL-1b and IL-23
cooperate to induce IL-17 from ILC3s [18], and finally, IL-18 can
replace IL-1b in combination with IL-23 to promote IL-17
secretion from cd T cells [19]. Additional signals such as those
mediated via pattern recognition receptors or NK cell receptors
found on ILCs may also contribute to full activation [20,21]. IL-17
secretion by ILC3s and cd T cells may in fact be regulated by the
integration of signals obtained from both cytokines and cell-bound
receptors. Of interest in the context of fungal infections are cd T
cells expressing TLR1, TLR2, and Dectin-1, which were shown to
produce IL-17 in response to PRR engagement and IL-23
stimulation, but independent of TCR signaling [22].
From Mice to Man: Do ILCs Play a Role in
Antifungal Immunity in Humans?
Most available data on ILCs comes from research with animal
models. However, ILCs were also identified in humans [23]. Like
their murine counterparts they reside in barrier tissues including
the skin and the intestine, but they can also be found in the blood
and secondary lymphoid organs, and they express RORct and
secrete IL-17 and IL-22 [23]. Although they likely contribute to
the homeostatic balance with the intestinal microflora in healthy
individuals, their accumulation in the intestine of IBD patients
indicates a detrimental role of ILC3s in the pathogenesis of human
inflammatory diseases [14]. Opportunistic fungal pathogens such
as Candida ssp. reside as part of the human commensal microflora
in the gastrointestinal tract and promote the formation of Candida-
specific CD4+ T cell memory in steady state. This is in contrast to
the murine intestinal flora, where the spectrum of Candida spp. is
more limited and subject to variation based on animal husbandry
and sanitary conditions [24]. Accordingly, in humans the fungal
load is generally thought to be controlled by the adaptive immune
system. Frequently cited evidence for this is provided by HIV+
individuals who commonly manifest oropharyngeal candidiasis
(thrush) when CD4+ T cell counts drop as a consequence of the
viral infection. Surprisingly the loss of intestinal CD4+ cells during
SIV infection in macaques—the simian equivalent of HIV in
humans—is accompanied by the loss of intestinal IL-17-secreting
ILC3s and the progression towards AIDS [25]. In another study,
ILC3-derived cytokine production (but not the number of ILC3s)
in the tonsils and buccal mucosa was found to be reduced during
SIV infection [26]. Together this raises the question whether ILC
numbers and/or effector functions are also affected in response to
HIV in humans and thus may contribute to the predisposition of
AIDS patients to fungal infection. Likewise, the genetic defects
identified to cause congenital forms of CMC have all been
associated with defects in adaptive IL-17 mediated immunity.
Many of them however may also affect innate IL-17 production
and a role of ILCs in the epidemiology of CMC should thus be
considered.
Do ILCs Impact on Long-term Protection?
Although ILCs are equipped for reacting promptly to acute
microbial offense, they do not only impact the immediate response
to infection but may also provide long-lasting effects with
beneficial or detrimental consequences for the host. In fact, ILCs
can limit the dissemination of commensals and thereby regulate
tissue homeostasis, and they can promote tolerance to commensal
bacteria by inhibiting adaptive T cell responses as animal
experiments have recently shown [27,28]. Conversely, ILCs have
been implicated in chronic situations of intestinal inflammation in
humans and mice and in the progression toward bacteria-induced
colon cancer in a mouse model [13,14,29]. ILCs may also
contribute to long-term protection from infections including those
caused by opportunistic fungi, to which we are constantly exposed.
The mechanisms, by which ILCs control sustained responses,
remain to be defined. An intriguing possibility involves effects of
ILCs on the adaptive immune system. Although no experimental
evidence is available to date, such a scenario is supported by the
observation that IL-17-secreting cd T cells can promote Th17
responses [30,31]. It is conceivable that ILCs could act similarly
and thereby modulate quantitative and/or qualitative aspects of T
cell differentiation. Future studies may provide evidence for this
and if so, they should clarify whether innate IL-17 acts directly on
T cells or whether it affects T cell differentiation by modulating the
priming APCs. It is intriguing to speculate that the ILC-mediated
effects could be linked to the recently proposed concept of trained
innate immunity, where monocytes provide long-term protection
from C. albicans [32].
Concluding Remarks
IL-17 producing ILCs are important new players of the immune
system, in particular in the host response to infectious agents,
including fungal pathogens. Complementary to their function as
immediate cytokine producers in response to infection, their
function may also have far-reaching consequences. Future studies
will provide a comprehensive understanding of ILCs as effectors as
well as modulators of the immune system.
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